Drug Profile
Filgrastim biosimilar - Sandoz
Alternative Names: EP2006; Filgrastim Hexal (Sandoz); Filgrastim-sndz; Zarxio; ZarzioLatest Information Update: 12 Nov 2021
Price :
$50
*
At a glance
- Originator Sandoz
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Febrile neutropenia
Most Recent Events
- 15 Jul 2020 Launched for Febrile neutropenia (Prevention) in Russia (IV)
- 15 Jul 2020 Launched for Febrile neutropenia (Prevention) in Russia (SC)
- 01 Jun 2018 Adverse events data from the phase III PIONEER and observational MONITOR-GCSF trial in Febrile neutropenia presented at the 54th Annual Meeting of the American Society of Clinical Oncology